Risk Factors of Bronchiectasis in Adult Patients with Common Variable Immunodeficiency

Gökhan AYTEKİN, Fatih CÖLKESEN, Eray YILDIZ, Şevket ARSLAN
Necmettin Erbakan University, Meram School of Medicine, Department of Internal Medicine, Division of Allergy and Clinical Immunology, Konya, Turkey

Corresponding Author: Gökhan Aytekin  ayteking@gmail.com

ABSTRACT

Objective: Common Variable Immunodeficiency (CVID) is a heterogeneous immune disorder characterized by frequent and recurrent upper and lower respiratory tract infections. Although immunoglobulin (Ig) replacement therapy (IgRT) reduces the frequency of infections, complications due to infections of the respiratory tract, particularly bronchiectasis, is still challenging and occur in approximately 20% of patients. Therefore, we aimed to identify independent predictors of bronchiectasis in adult patients with CVID.

Materials and Methods: We retrospectively analyzed the hospital records of 45 CVID patients (26 male, 19 female). Additionally, we classified the patients according to the presence of bronchiectasis. Bronchiectasis was confirmed by high resolution computed tomography of thorax.

Results: Forty-five patients with CVID (F:19 [42.2%], M: 26 [57.8%]) were included in the study (age: 36.52 ± 12.86). Bronchiectasis was observed in 60% of the study group. Univariate regression analysis revealed that IgG levels (OR: 4.889, 95% CI, 0.485-0.959, p: 0.012) and IgA levels (OR: 2.559, 95% CI, 0.097-1.235, p: 0.030) at the time of diagnosis and the percentage of switched memory B cells (OR: 0.848, 95% CI, 0.730-0.984, p: 0.030) were significantly associated with bronchiectasis. Multivariate regression analysis showed that a lower percentage of switched memory B cells (OR: 0.853, 95% CI, 0.733-0.991, p: 0.038) and a low platelet count (OR: 1.000, 95% CI, 1.000-1000, p: 0.026) were also independent predictors of bronchiectasis.

Conclusion: Clinicians should be alert for CVID patients with reduced switched memory B cells and low platelet counts in order to detect and treat complications associated with bronchiectasis at an early stage.

Keywords: Switched memory B cells, bronchiectasis, platelets, Common Variable Immunodeficiency

INTRODUCTION

Common Variable Immunodeficiency (CVID) is a heterogeneous immune disorder characterized by frequent and recurrent upper and lower respiratory tract infections, autoimmune disorders, granulomatous diseases and predisposition to malignancy (1, 2). In addition, CVID is the most common symptomatic antibody disorder in adults (1). In the absence of other well-defined immunodeficiency conditions, CVID is diagnosed with low levels of immunoglobulin (Ig) G (IgG), IgA and/or IgM, and inadequate antibody response to vaccines or infections (3, 4). Ig replacement therapy (IgRT) either by the intravenous or subcutaneous route is the cornerstone of treatment. Although IgRT, use of prophylactic antibiotics and monoclonal antibodies such as infliximab, rituximab, adalimumab etc. reduce the frequency of infections, complications due to recurrent and frequent infections of the respiratory tract, particularly bronchiectasis and granulomatous lung disease, are still challenging and occur in approximately 20% of patients (5). In this study, we aimed to investigate the risk factors associated with bronchiectasis in adult patients with CVID who were followed-up at our Clinical Immunology Department.

MATERIALS and METHODS

In our study, we retrospectively analyzed the data in the personal hospital records of 45 patients (26 male, 19 female), in case they have been sufficient. CVID was
diagnosed according to the updated diagnostic criteria of the European Society for Immunodeficiency (ESID) (3). Bronchiectasis have been confirmed by high-resolution computed tomography. The study protocol was approved by the Ethics committee. Informed consent was obtained from study participants.

Serum Ig concentrations (IgG, IgM, IgA, and IgE) were determined by particle-enhanced immunonephelometry using a Siemens BN II/BN ProSpec system (Eschborn, Germany). Peripheral blood lymphocyte subsets were measured with a BD FACSCanto II 8-color flow cytometer system (Erembodegem, Belgium) with fluorescent labeled antibodies. CD3⁺ T cells, helper T cells (CD4⁺ T cells), cytotoxic T cells (CD8⁺ T cells), CD19⁺ B cells, natural killer (CD3⁻ CD16⁺ CD56⁺) cells, switched memory (IgD⁻ IgM CD27⁺) B cells, and recent thymic emigrant (CD4⁺ CD31⁺ CD45RA⁺) T cells were measured.

Spirometric measurements were obtained with an nSpire ZAN 100 spirometer. Forced vital capacity (FVC), forced expiratory volume in one second (FEV1), peak expiratory flow (PEF), mean expiratory flow 25-75% and FEV1/FVC were recorded. FEV1 ≥ 80% of the predicted ratio was considered normal.

A statistical analysis was performed with IBM SPSS Statistics, Version 22 software (New York, United States). Parametric statistics were presented as mean ± standard deviation and nonparametric statistics were expressed as median (minimum–maximum). Descriptive data were presented as frequencies and percentages and compared using the Chi-square test. Comparisons between baseline characteristics were performed with an independent Student’s t-test or Chi-square test where appropriate. A binary logistic regression analysis was performed to determine the independent predictors of bronchiectasis.

RESULTS

Forty-five patients with CVID (F: 19 [42.2%], M: 26 [57.8%]) were included in the study (age: 36.52 ± 12.86). There was parental consanguinity in 53.3% of the patients (parents were from the same village in 68.9% of patients) There was bronchiectasis in 60% of the patients. The mean diagnostic delay was 104.22 ± 91.9 months. Including the 13 (28.9%) receiving subcutaneous IgRT, all patients have been receiving IgRT. Baseline demographic, clinical, and laboratory parameters of the patients are summarized in Table I.

In the current study, patients with bronchiectasis had had lower IgM levels, CD4/CD8 ratios and percentages of B cells at the time of diagnosis. Additionally, patients with bronchiectasis had lower FEV1, PEF, MEF25-75 and FEV1/FVC, but this difference was not statistically significant.

Univariate regression analysis revealed that IgG levels (OR: 4.889, 95% CI 0.485-0.959, p: 0.012), IgA levels (OR: 2.559, 95% CI, 0.097-1.235, p: 0.030) at the time of diagnosis and the percentage of switched memory B cells (OR: 0.848, 95 % CI, 0.730-0.984, p: 0.030) were significantly associated with bronchiectasis. Multivariate regression analysis showed that a lower percentage of switched memory B cells (OR: 0.853, 95 % CI, 0.733-0.991, p: 0.038) and a low platelet count (OR: 1.000, 95 % CI, 1.000-1000, p: 0.026) were also independent predictors of bronchiectasis (Table II).

DISCUSSION

CVID is the most common symptomatic immune disorder in adults with a deficiency of switched memory B cells (5, 6). Although adequate Ig replacement in addition to use of prophylactic antibiotics and monoclonal antibodies such as infliximab, rituximab, adalimumab etc. have reduced the mortality and morbidity rates associated with CVID, complications due to recurrent and frequent infections of the respiratory tract, particularly bronchiectasis and granulomatous lung disease, are still challenging and occur in approximately 20% of patients (5).

In our study group, parental consanguinity was found in 53.3% of patients, which was an unexpectedly high rate. In studies conducted in Turkey, Ardeniz et al. reported a rate of 30% and Musabak et al. reported a rate of 12.9% for consanguineous marriages (7, 8). In studies conducted in other countries, Oksenhendler et al. and Aghamohammadi et al. reported lower rates at 5.4% and 8% , respectively (9, 10). Additionally, in this study, 45 Turkish CVID patients were classified according to the presence of bronchiectasis. Bronchiectasis was reported in 60% of these CVID patients. Thickett et al. reported that 51% of patients with CVID had bronchiectasis (11). In another study consisting of 27 CVID and 10 XLA patients, 55% of the patients had bronchiectasis (12). As far as we know, the highest percentage for bronchiectasis was given as 73% in a study by Kainulainen et al (13). In Turkey, Ardeniz et al. reported that 48% of patients with CVID had bronchiectasis (7).
Our results showed a higher rate compared to theirs. In our study, parental consanguinity was found in 53.3% of patients. Kutukculer et al. and Rivoisy et al. reported that parental consanguinity was associated with a severe phenotype in CVID and this may be the main reason for the high percentages of bronchiectasis in our study group (14, 15). Due to the heterogeneity of the disease, lack of awareness among clinicians concerning primary immunodeficiencies (PID) and the misconception that immunodeficiencies are childhood diseases, delayed diagnosis is common especially in adult CVID patients (11). The mean diagnostic delay was 104 ± 91.9 months in the present study, which is consistent with Quinti et al.’s report (16). Furthermore, Ardeniz et al. and Musabak et al. also reported similar periods of delayed diagnosis in Turkey (7, 8).

Patients with bronchiectasis had statistically significantly lower IgG and IgA levels and switched memory B cells at the time of diagnosis compared to the patients

Table I: Baseline demographic, clinical, and laboratory parameters of the study population

|                                | Total (n=45) | Bronchiectasis (-) (n=18) | Bronchiectasis (+) (n=27) | p   |
|--------------------------------|--------------|---------------------------|---------------------------|-----|
| Gender (female), n(%)          | 19 (42)      | 9 (50)                    | 10 (37)                   | 0.388 |
| Age                            | 36.52 ± 12.86| 36.94 ± 15.62             | 35.52 ± 10.96             | 0.915 |
| Consanguinity n(%)             | 31 (68.9)    | 12 (66.7)                 | 19 (70.4)                 | 0.793 |
| Body Mass Index kg/m²           | 24.90 ± 5.74 | 25.49 ± 4.51              | 24.50 ± 6.49              | 0.577 |
| Smoking, n(%)                  | 20 (44.4)    | 7 (38.9)                  | 13 (48.1)                 | 0.540 |
| SCIG, n(%)                     | 13 (28.9)    | 5 (27.8)                  | 8 (29.6)                  | 0.893 |
| Diagnostic Delay, months       | 104.22 ± 91.88| 110.56 ± 88.84            | 100.00 ± 95.28            | 0.710 |
| IgG dose /mg/month              | 400 (200-800)| 400 (200-800)             | 400 (200-800)             | 0.601 |
| IgM, at diagnosis, (g/dl)       | 2.75 (0.33-6.90)| 3.67 (0.33-6.80)         | 1.56 (0.33-6.90)          | 0.016 |
| Lymphocytes count (mm³)         | 3600 (700-12500) | 3320 (700-6300)         | 3600 (1000-1250)          | 0.069 |
| Platelet count (mm³)            | 212722.22 ± 93786.00 | 230074.07 ± 84439.75     | 187694.44 ± 103273.07     | 0.130 |
| CD3 (%)                        | 77.50 ± 10.19| 74.37 ± 9.15              | 79.59 ± 10.46             | 0.092 |
| CD4 (%)                        | 33.64 ± 13.91| 35.81 ± 13.64             | 32.20 ± 14.18             | 0.401 |
| CD8 (%)                        | 36 (19-74)   | 33.50 (21-74)             | 41 (19-74)                | 0.088 |
| CD4/CD8                        | 1.02 ± 0.78  | 1.14 ± 0.74               | 0.94 ± 0.80               | 0.398 |
| CD19 (%)                       | 7.22 ± 5.75  | 7.71 ± 5.87               | 6.90 ± 5.75               | 0.648 |
| CD16-56 (%)                    | 9.37 ± 6.38  | 11.03 ± 5.96              | 8.26 ± 6.51               | 0.154 |
| CD3(+)CD4(-)CD8(-) T cell      | 2.00 (0-27)  | 1.00 (0-11)               | 2.00 (0-27)               | 0.542 |
| IgD(-) IgM (-) CD27 (+) B cell | 1.20 (0-52)  | 4.40 (0-1.52)             | 1.0 (0-20.30)             | 0.005 |
| CD4(+) CD31(+) CD45RA (+) T cell (%) | 16 (0.90-69) | 16 (1.90-59.60)         | 16 (0.90-69)              | 0.935 |
| TmAb (antithyroid microsomal antibodies), median (min-max) | 13.30 (0.1-47.80) | 14.60 (0.10-24.20)     | 12.90 (1-47.80)           | 0.410 |
| FEV1≤80%, n (%)                | 29 (64.4)    | 11 (61.1)                 | 18 (66.7)                 | 0.703 |
| FEV1, %                        | 71.57 ± 17.15| 73.92 ± 16.49             | 70.00 ± 17.71             | 0.459 |
| FEV1/FVC, %                    | 98.19 ± 10.01| 98.59 ± 9.94              | 97.93 ± 10.24             | 0.829 |
| PEF, %                         | 58.99 ± 20.74| 60.35 ± 19.60             | 58.09 ± 21.79             | 0.725 |
| MEF25-75, %                    | 58.96 ± 24.68| 63.62 ± 23.80             | 55.86 ± 25.20             | 0.307 |
without bronchiectasis. Also, when multivariate analyses were performed, we found that a reduced percentage of switched memory B cells and lower platelet counts are independent risk factors for bronchiectasis. Agematsu et al. reported that in peripheral blood, CD27+ B cells could be classified into two distinct groups: IgD+ CD27+ B cells (non-switched memory B cells) which predominantly secreted IgM, and IgD- CD27+ B cells (switched memory B cells) which synthesized only one of IgG, IgM or IgA (17). Although, decreased switched memory B cells (IgD- IgM- CD27+) in CVID patients are a well-defined characteristic of the disease (18, 19) and CVID has been classified based on memory B cells for over two decades (20), there are conflicting reports on the association between chronic lung disease and decreased isotype-switched memory B cells (21-24). Llobet et al. reported that children with decreased memory B cells had severe complications like bronchiectasis (23). Furthermore, Dectova et al. reported that the memory B cell count was associated with severe respiratory outcomes in CVID (22). Alachkar et. al. reported that the percentage of memory B cells but not immunoglobulin concentration was associated with bronchiectasis (25). Our results are similar to this report. Decreased switched memory B cells cause reduced IgG production and less effective pneumococcal antibodies. Therefore, patients have more frequent respiratory tract infections, which can cause higher rates of bronchiectasis in patients with CVID (26). On the other hand, some patients with severe hypogammaglobulinemia do not suffer from bronchiectasis. Non-switched memory B cells can still synthesize sufficient anti-pneumococcal IgM and these antibodies may protect the patient from the development of bronchiectasis (26).

Bronchiectasis is not only associated with recurrent sinopulmonary infections, but is also proof and indication of other inflammatory conditions (27). Kellner et. al reported that CVID patients with bronchiectasis had more autoimmune complications such as autoimmune hematologic diseases, hepatomegaly, splenomegaly and lymphadenopathy than CVID patients without bronchiectasis (28). Regulatory T cells (T-regs) play an important role in the preservation of immune homeostasis (29). Romberg et al. reported that a decreased number of T-regs, reduced T-reg function and an increased number of follicular T cells in the germinal center of lymph nodes might correlate with fewer isotype switched memory B cells (30). Therefore, reduced T-reg function may contribute to the development of bronchiectasis. Although some monogenic immunodeficiencies such as PI3KD (A phosphoinositide 3-kinase delta) gain of function mutation may lead to bronchiectasis, the genetic analysis of any of our patients has not been concluded yet.

Although thrombocytes may not have a direct association with chronic lung disease, the relationship between these two conditions in CVID patients has been shown in many studies (6, 31). In this patient group, low platelet counts may be an indicator of splenic sequestration due to

### Table II: Univariate and multivariate binomial regression analyses demonstrating the relationship between baseline characteristics and bronchiectasis

| Variables                      | Univariate (OR: 95% CI) | P value | Multivariate (OR: 95% CI) | P value |
|-------------------------------|-------------------------|---------|---------------------------|---------|
| IgG, at diagnosis             | 4.889 (0.485-0.959)     | 0.012   | 1.281 (0.421-1.004)       | 0.809   |
| IgM, at diagnosis             | 1.773 (0.505-1.283)     | 0.108   | 1.086 (0.576-2.047)       | 0.798   |
| IgA, at diagnosis             | 2.559 (0.097-1.235)     | 0.030   | 0.408 (0.955-1.113)       | 0.606   |
| Neutrophil count              | 1.000 (1000-1001)       | 0.170   | 1000 (1000-1001)          | 0.149   |
| Lymphocyte count              | 1.000 (1000-1001)       | 0.275   | 1000 (0.999-1.000)        | 0.280   |
| Lymphopenia                   | 3.520 (0.918-13.501)    | 0.067   | 0.370 (0.073-1.867)       | 0.229   |
| Platelet count                | 1000 (1000-1000)        | 0.134   | 1000 (1000-1000)          | 0.026   |
| CD3 (%)                       | 1.057 (0.989-1.129)     | 0.103   | -                         | -       |
| CD8 (%)                       | 1.041 (0.992-1.092)     | 0.106   | -                         | -       |
| CD16-56 (%)                   | 0.932 (0.845-1.027)     | 0.156   | -                         | -       |
| IgD(-) IgM (-) CD27 (+) B cell (%) | 0.848 (0.730-0.984) | 0.030   | 0.853 (0.733-0.991)       | 0.038   |
splenomegaly, and/or may be an expression of increased immune dysregulation and autoimmunity. Maglione et al. found that thrombocytopenia was significantly associated with chronic lung disease in patients with CVID (32). In the current study, we found that platelet counts were lower in patients with bronchiectasis than in those without bronchiectasis, and low platelet counts were independent risk factors for the development of bronchiectasis. Although infections are the main cause of bronchiectasis, there are other inflammatory conditions in addition to infections in the continuation of bronchiectasis (27) and presumably, decreased platelet count in CVID patients is a reflection of these additional inflammatory conditions.

Our study has some limitations, such as a small study population, a single center experience and cross-sectional design. Also, we could not analyze the relationship between the severity of bronchiectasis and other immunological parameters.

CONCLUSION

In conclusion reduced percentage of switched memory B cells and reduced platelet counts are independent predictors for the development of bronchiectasis, and therefore, patients with CVID who have decreased switched memory B cells and reduced platelet counts require close clinical monitoring to detect and treat complications associated with bronchiectasis at an early stage.

ACKNOWLEDGEMENT

None.

CONFLICT of INTEREST

None.

REFERENCES

1. Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: Clinical and immunological features of 248 patients. Clin Immunol 1999;92(1):34-48.
2. Tam JS, Routes JM. Common variable immunodeficiency. Am J Rhinol Allergy 2013;27(4):260-5.
3. Conley ME, Notarangelo LD, Etzioni A. Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies). Clin Immunol 1999;93(3):190-7.
4. Bousfiha A, Jeddane L, Picard C, Alal F, Bobby Gaspar H, Al-Herz W, et al. The 2017 IUIS Phenotypic classification for primary immunodeficiencies. J Clin Immunol 2018;38(1):129-43.
5. Ahn S, Cunningham-Rundles C. Role of B cells in common variable immune deficiency. Expert Rev Clin Immunol 2009;5(5):557-64.
6. Wehr C, Kivioja T, Schmitt C, Ferry B, Witte T, Eren E, et al. The EUROclass trial: Defining subgroups in common variable immunodeficiency. Blood 2008;111(1):77-85.
7. Ardeniz O, Basoglu OK, Günsar F, Unsal A, Bayraktaroglu S, Mete N, et al. Clinical and immunological analysis of 23 adult patients with common variable immunodeficiency. J Investig Allergol Clin Immunol 2010;20(3):222-36.
8. Musabik UH, Demirel F, Yesillik S, Baysan A, Selcuk A, Kartal O, et al. Adults with common variable immunodeficiency: A single-center experience. Turk J Med Sci 2017;47(1):1-12.
9. Oksenhendler E, Gerard L, Fieschi C, Malphettes M, Mouillot G, Jaussaud R, et al. Infections in 252 patients with common variable immunodeficiency. Clin Infect Dis 2008;46(10):1547-54.
10. Aghamohammadi A, Abdulhassani H, Moazzami K, Parvaneh N, Rezaei N. Correlation between common variable immunodeficiency clinical phenotypes and parental consanguinity in children and adults. J Investig Allergol Clin Immunol 2010;20(3):372-9.
11. Thickett KM, Kumararatne DS, Banerjee AK, Dudley R, Stableforth DE. Common variable immune deficiency: Respiratory manifestations, pulmonary function and high-resolution CT scan findings. QIM 2002;95(10):655-62.
12. Curtin JJ, Webster AD, Farrant J, Katz D. Bronchiectasis in hypogammaglobulinaemia--a computed tomography assessment. Clin Radiol 1991;44(2):82-4.
13. Kainulainen L, Varpula M, Liippo K, Svedstrom E, Nikoskelainen J, Ruuskanen O. Pulmonary abnormalities in patients with primary hypogammaglobulinemia. J Allergy Clin Immunol 1999;104(5):1031-6.
14. Rivoisy C, Gerard L, Boutboul D, Malphettes M, Fieschi C, Durieu I, et al. Parental consanguinity is associated with a severe phenotype in common variable immunodeficiency. J Clin Immunol 2012;32(1):98-105.
15. Kutukculer N, Gulez N, Karaca NE, Aksu G, Berdeli A. Three different classifications, B lymphocyte subpopulations, TNFRSF13B (TACI), TNFRSF13C (BAFF-R), TNFSF13 (APRIL) gene mutations, CTLA-4 and ICOS gene polymorphisms in Turkish patients with common variable immunodeficiency. J Clin Immunol 2012;32(6):1165-79.
16. Quinti I, Soresina A, Spadaro G, Martino S, Donnanno S, Agostini C, et al. Long-term follow-up and outcome of a large cohort of patients with common variable immunodeficiency. J Clin Immunol 2007;27(3):308-16.
17. Agematsu K, Nagumo H, Yang FC, Nakazawa T, Fukushima K, Ito S, et al. B cell subpopulations separated by CD27 and crucial collaboration of CD27+ B cells and helper T cells in immunoglobulin production. Eur J Immunol 1997;27(8):2073-9.
18. Brouet JC, Chedeville A, Fermand JP, Royer B. Study of the B cell memory compartment in common variable immunodeficiency. Eur J Immunol 2000;30(9):2516-20.
19. Jacquot S, Macon-Lemaître L, Paris E, Kobata T, Tanaka Y, Morimoto C, et al. B cell co-receptors regulating T cell-dependent antibody production in common variable immunodeficiency: CD27 pathway defects identify subsets of severely immunocompromised patients. Int Immunol 2001;13(7):871-6.
20. Warnatz K, Denz A, Drager R, Braun M, Groth C, Wolff-Vorbeck G, et al. Severe deficiency of switched memory B cells (CD27(+)IgM(-)IgD(-)) in subgroups of patients with common variable immunodeficiency: A new approach to classify a heterogeneous disease. Blood 2002;99(5):1544-51.
21. Moratto D, Gulino AV, Fontana S, Mori L, Pirovano S, Soresina A, et al. Combined decrease of defined B and T cell subsets in a group of common variable immunodeficiency patients. Clin Immunol 2006;121(2):203-14.
22. Detkova D, de Gracia J, Lopes-da-Silva S, Vendrell M, Alvarez A, Guarner L, et al. Common variable immunodeficiency: Association between memory B cells and lung diseases. Chest 2007;131(6):1883-9.
23. Llobet MP, Soler-Palacin P, Detkova D, Hernandez M, Caragol I, Espanol T. Common variable immunodeficiency: 20-yr experience at a single centre. Pediatr Allergy Immunol 2009;20(2):113-8.
24. Vodigani M, Aghamohammadi A, Samadi M, Moin M, Hadijati J, Mirahmadian M, et al. Analysis of class-switched memory B cells in patients with common variable immunodeficiency and its clinical implications. J Investig Allergol Clin Immunol 2007;17(5):321-8.
25. Sanchez-Ramon S, Radigan L, Yu JF, Bard S, Cunningham-Rundles C. Memory B cells in common variable immunodeficiency: Clinical associations and sex differences. Clin Immunol 2008;128(3):314-21.
26. Ko J, Radigan L, Cunningham-Rundles C. Immune competence and switched memory B cells in common variable immunodeficiency. Clin Immunol 2005;116(1):37-41.
27. Cunningham-Rundles C. Common variable immune deficiency: Dissection of the variable. Immunol Rev 2019;287(1):145-61.
28. Kellner ES, Fuleihan R, Cunningham-Rundles C, Consortium U, Wechsler JB. Cellular defects in CVID patients with chronic lung disease in the USIDNET Registry. J Clin Immunol 2019;39(6):569-76.
29. Qiu R, Zhou L, Ma Y, Zhou L, Liang T, Shi L, et al. Regulatory T cell plasticity and stability and autoimmune diseases. Clin Rev Allergy Immunol. 2018 Nov 17. doi: 10.1007/s12016-018-8721-0. [Epub ahead of print]
30. Romberg N, Le Coz C, Glauzy S, Schickel JN, Trofa M, Nolan BE, et al. Patients with common variable immunodeficiency with autoimmune cytopenias exhibit hyperplastic yet inefficient germinal center responses. J Allergy Clin Immunol 2019;143(1):258-65.
31. Bondioni MP, Soresina A, Lougaris V, Gatta D, Plebani A, Maroldi R. Common variable immunodeficiency: computed tomography evaluation of bronchopulmonary changes including nodular lesions in 40 patients. Correlation with clinical and immunological data. J Comput Assist Tomogr 2010;34(3):395-401.
32. Maglione PJ, Overbey JR, Cunningham-Rundles C. Progression of common variable immunodeficiency interstitial lung disease accompanies distinct pulmonary and laboratory findings. J Allergy Clin Immunol Pract 2015;3(6):941-50.